



HU000028615T2

(19) **HU****MAGYARORSZÁG**
Szellemi Tulajdon Nemzeti Hivatala(11) Lajstromszám: **E 028 615**(13) **T2**

EURÓPAI SZABADALOM

SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 09 833924**(22) A bejelentés napja: **2009. 12. 21.**(51) Int. Cl.: **A61K 393/95** (2006.01)**A61P 19/02** (2006.01)**C07K 16/28** (2006.01)

(96) Az európai bejelentés bejelentési száma:

EP 20090833924

(97) Az európai bejelentés közzétételi adatai:

EP 2376121 A1 **2010. 07. 01.**

(86) A nemzetközi (PCT) bejelentési szám:

PCT/AU 09/001672

(97) Az európai szabadalom megadásának meghirdetési adatai:

EP 2376121 B1 **2016. 03. 09.**

(87) A nemzetközi közzétételi szám:

WO 10071924

(30) Elsőbbségi adatok:

139679 P **2008. 12. 22.** **US****164486 P** **2009. 03. 30.** **US**

(73) Jogosult(ak):

The University of Melbourne, Parkville, Victoria
3052 (AU)

(72) Feltaláló(k):

HAMILTON, John Allan, Carlton Victoria 3053 (AU)**COOK, Andrew David, Carlton Victoria 3053 (AU)**

(74) Képviselő:

Danubia Szabadalmi és Jogi Iroda Kft.,
Budapest

(54)

Oszteoarthritis kezelés

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 376 121 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
09.03.2016 Bulletin 2016/10

(51) Int Cl.:
A61K 39/395 ^(2006.01) **A61P 19/02** ^(2006.01)
C07K 16/28 ^(2006.01)

(21) Application number: **09833924.5**

(86) International application number:
PCT/AU2009/001672

(22) Date of filing: **21.12.2009**

(87) International publication number:
WO 2010/071924 (01.07.2010 Gazette 2010/26)

(54) **OSTEOARTHRITIS TREATMENT**

BEHANDLUNG VON OSTEOARTHRITIS

TRAITEMENT DE L'ARTHROSE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK SM TR**

(30) Priority: **22.12.2008 US 139679 P**
30.03.2009 US 164486 P

(43) Date of publication of application:
19.10.2011 Bulletin 2011/42

(60) Divisional application:
15194091.3

(73) Proprietor: **The University of Melbourne
Parkville, Victoria 3052 (AU)**

(72) Inventors:
• **HAMILTON, John Allan
Carlton
Victoria 3053 (AU)**
• **COOK, Andrew David
Carlton
Victoria 3053 (AU)**

(74) Representative: **Price, Susanna Clare Hopley et al
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS (GB)**

(56) References cited:
**WO-A1-2007/110631 WO-A1-2008/141391
WO-A1-2009/064399 WO-A2-2007/092939
WO-A2-2008/064321 WO-A2-2009/038760
WO-A2-2009/134805 US-A1- 2002 010 126**

- **N. AMOS ET AL: "Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor I B reveals that most, but not all, inflammatory and destructive mediators are NF B dependent", RHEUMATOLOGY, vol. 45, no. 10, 1 January 2006 (2006-01-01), pages 1201-1209, XP055053858, ISSN: 1462-0324, DOI: 10.1093/rheumatology/kei078**
- **VAN HOLTEN JUDITH ET AL: "Treatment with recombinant interferon-[beta] reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis", ARTHRITIS RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 6, no. 3, 23 March 2004 (2004-03-23), pages R239-R249, XP021011482, ISSN: 1465-9905**
- **COOK ANDREW D ET AL: "Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease", ARTHRITIS RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 3, no. 5, 11 June 2001 (2001-06-11), pages 293-298, XP021020639, ISSN: 1465-9905, DOI: 10.1186/AR318**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 376 121 B1

Description**FIELD OF THE INVENTION**

5 **[0001]** The present invention relates to an antagonist of GM-CSF for use in the treatment of osteoarthritis (OA), wherein the antagonist is an antibody specific for GM-CSF.

BACKGROUND OF THE INVENTION

10 **[0002]** Osteoarthritis (OA), also known as degenerative arthritis, is a disease most prevalent in the old and obese. OA is a disease of the articular joints, but, unlike rheumatoid arthritis (RA), the disease is not systemic, usually affecting only one or a few joints. The disease leads to total destruction of the articular cartilage, sclerosis of the underlying bones, and osteophyte formation, resulting in loss of movement and pain. The ultimate result is often the need for a total joint replacement.

15 **[0003]** OA affects about ~21 million people in the US, comprises 25% of all primary care physician visits, and accounts for 50% of all NSAID (non steroidal anti inflammatory drugs) prescriptions. There is currently no treatment available which slows or halts disease progression; today's drugs merely treat the symptoms. The incidence and severity of the disease increase with age. By the age of 65, 80% of Americans show radiographic evidence of OA though only 60% of them will be symptomatic. 65% of all joint disease by the age of 65 are OA. In 2006, there were 735,000 OA-related US hospitalizations.

20 **[0004]** Current OA drugs treat the symptoms of OA rather than the disease itself. Commonly used drugs in the treatment of OA include Non-steroidal anti-inflammatory drugs (NSAIDs), such as diacerin, voltaren, mobic and arthrotec (generic names: diclofenac, misoprostol, meloxicam). NSAIDs are mainly oral compounds which act by inhibiting prostaglandin synthesis in the central nervous system (CNS). Other commonly used drugs include non-narcotic analgesics, such as ultram (tramadol), COX-2 inhibitors, such as celebrax and arcoxia (celecoxib, etoricoxib), narcotic analgesics, such as duragesic (dextropropoxyphene fentanyl), hyaluraonic acids, such as suparts, hyalgan, orthovisc and synvisc (Hylan G-F20), and corticosteroids, such as prednisolone and methyl prednisolone. Present treatments for OA intend to obviate the need for surgery through tissue engineering, such as chondrocyte transplantation; however, these treatments are only applicable for the treatment of last stage OA. Other approaches in the treatment of OA that are considered include prolotherapy, in which an irritant, such as dextrose, is injected into the affected joint, thereby causing an acute inflammatory reaction, but also strengthening and hopefully healing the tissues, ligaments, tendons, and cartilage. There is, thus, a high unmet medical need for the treatment of OA.

30 **[0005]** Some cytokines are known to be involved in osteoarthritis (Blom et al., Current Drug Targets (2008) 8:283). A few cytokines, such as IL-1, a 'destructive' cytokine, and the anabolic growth factor transforming growth factor β (TGFD β) are considered as potential drug targets.

35 **[0006]** Granulocyte macrophage colony-stimulating factor (GM-CSF) is a cytokine that functions as a white blood cell growth factor. GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. Monocytes exit the circulation and migrate into tissue, whereupon they mature into macrophages. It is, thus, part of the natural immune/inflammatory cascade, by which activation of a small number of macrophages can rapidly lead to an increase in their numbers, a process crucial for fighting infection. The active form of GM-CSF is found extracellularly as a homodimer. In particular, GM-CSF has been identified as an inflammatory mediator in autoimmune disorders, like rheumatoid arthritis (RA), leading to an increased production of pro-inflammatory cytokines, chemokines and proteases and, thereby, ultimately to articular destruction.

40 **[0007]** WO 06/0234412 discloses numerous biomarkers for osteoarthritis, which were identified by protein microarrays. One of the biomarkers identified is GM-CSF, for which a four-fold up-regulation is reported in OA tissue. However, no indication or suggestion is provided that GM-CSF may also be a point for therapeutic intervention, and a mere four-fold up-regulation in OA tissue, as identified with the technology disclosed in WO 06/0234412, also does not suggest the same. In a related vein, Devalaraja et al (US20020141994A1) cursorily mention OA among a long list of potentially suitable indications suitable for treatment with antagonists of colony stimulating factors. The list of indications includes atherosclerosis, sepsis, asthma, autoimmune disease, osteoporosis and rheumatoid arthritis. Besides other colony stimulating factors, such as M-CSF and G-CSF, GM-CSF is one of the colony stimulating factors mentioned in Devalaraja et al. Indeed, Devalaraja et al. include no data or other insights as to why antagonizing GM-CSF would be appropriate to treat a subject suffering from OA.

50 **[0008]** Document Amos et al, Rheumatology 10:1201-1209, 2004 discloses that adenovirus-mediated overexpression of the NF- κ B inhibitor I κ B α in osteoarthritis synovial cells, inhibits the production of various cytokines, including GM-CSF. Document van Holten et al, Arthritis Res Ther: 6:R239-R249, 2004 shows that IFN- β reduces expression of IL-6, IL-8, and GM-CSF in rheumatoid arthritis and osteoarthritis fibroblast-like synoviocytes and correlates with reduced NF- κ B activity. Document Cook et al, Arthritis Res 3:293-298, 2001 shows that treatment with a neutralizing anti-GM-CSF

antibody ameliorates the symptoms of collagen-induced arthritis, a commonly used model for rheumatoid arthritis.

SUMMARY OF THE INVENTION

[0009] [The present invention, for the first time, demonstrates that GM-CSF is a valid target for the treatment of OA. This finding is new, and the prior art does not teach, suggest or provide any rationale for such a point of intervention in the treatment of OA. Accordingly, the invention provides, an antagonist of GM-CSF for use in the treatment of osteoarthritis, wherein the antagonist is an antibody specific for GM-CSF.

[0010] In another aspect, the present invention is directed to a composition comprising a GM-CSF antagonist for use in the treatment of osteoarthritis, wherein the antagonist is an antibody specific for GM-CSF and further wherein said composition further comprises one or more pharmaceutically acceptable carriers and/or diluents.

[0011] Also disclosed is the use of a GM-CSF antagonist, wherein the GM-CSF antagonist is an antibody specific for GM-CSF, in the preparation of a medicament in the treatment of osteoarthritis.

[0012] Throughout this specification, unless the context requires otherwise, the words "comprise", "have" and "include" and their respective variations such as "comprises", "comprising", "has", "having", "includes" and "including" will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

BRIEF DESCRIPTION OF THE DRAWINGS

[0013]

Figure 1 shows quantitative data for joint damage in different regions assessed by histological scoring. The experimental set-up and the scoring system are described in Example 2. "Lat." stands for lateral, "Med." stands for medial. Statistical analysis was performed via Mann-Whitney. The data are statistically significant for Lat. Femur ($p=0.02$), Lat Tibia ($p=0.003$), Med, Tibia ($p=0.001$), and over all regions (Mean; $p=0.002$).

Figure 2 shows exemplary histology sections of healthy control knees. Magnification is 100x. No cartilage damage, osteophyte formation, synovitis or deformations can be seen. S = synovial lining, C = cartilage layer.

Figure 3 shows exemplary histology sections of the left knees of C57/BL6 mice in a model of collagenase-induced OA. Magnification of the individual sections is indicated in the Figures. The top row of pictures shows that cartilage damage, osteophyte formation and synovitis are evident. O = osteophyte. S = synovial lining. The bottom row of pictures shows that joint deformation is also present.

Figure 4 shows exemplary histology sections of the left knees of GM-CSF^{-/-} mice in a model of collagenase-induced OA. Magnification of the individual sections is indicated in the Figures. As can be seen, the abnormalities and/or damages are much less severe compared to the C57/BL6 mice (see Figure 3) and are comparably to the healthy control mice (see Figure 2). O = osteophyte. S = synovial lining.

Figure 5 shows the knee joint histology scoring of the therapeutic treatment with a GM-CSF antibody in a mouse model of OA. Lat.=Lateral. Med.=Medial. Results are expressed as mean \pm SEM. As can be seen mice treated with anti-GM-CSF antibody show less disease.

Figure 6 shows the result of an experiment assessing the hind limb weight distribution in an incapacitance meter. Data are significant (unpaired t-test) from day 27 post OA induction onwards, as indicated in the graph.

DETAILED DESCRIPTION OF THE INVENTION

[0014] The present invention demonstrates that GM-CSF is a valid target for the treatment of OA. In this respect, the invention provides, in one aspect, an antagonist of GM-CSF for use in the treatment of osteoarthritis, wherein the antagonist is an antibody specific for GM-CSF.

[0015] Disclosed are methods of using such a GM-CSF antagonist to bring about a prophylactic or therapeutic benefit in the field of OA.

[0016] Also disclosed are therapeutic methods comprising the administration of a therapeutically effective amount of such a GM-CSF antagonist to a subject in need of such treatment. A "therapeutically effective amount" or "effective amount", as used herein, refers to the amount of such a

GM-CSF antagonist necessary to elicit the desired biological response. In accordance with the subject invention, the therapeutic effective amount is the amount of such a GM-CSF antagonist necessary to treat and/or prevent osteoarthritis.

[0017] "GM-CSF antagonists", as used herein, includes GM-CSF antagonists in its broadest sense; any molecule which inhibits the activity or function of GM-CSF, or which by any other way exerts a therapeutic effect on GM-CSF is included. The term GM-CSF antagonists may include, but is not limited to, antibodies specifically binding to GM-CSF, inhibitory nucleic acids specific for GM-CSF or small organic molecules specific for GM-CSF. Also within the meaning of the term GM-CSF antagonist are antibodies specifically binding to the GM-CSF receptor, inhibitory nucleic acids specific for the GM-CSF receptor or small organic molecules specific for the GM-CSF receptor.

[0018] For reviews see Ghose et al, J Combin Chem: 1:55-68, 1999 and Lipinski et al, Adv Drug Del Rev 23:3-25, 1997.

[0019] A GM-CSF antagonist for use in the present invention is an antibody specific for GM-CSF. Such an antibody may be of any type, such as a murine, a rat, a chimeric, a humanized or a human antibody. A "human" antibody or functional human antibody fragment is hereby defined as one that is not chimeric (e.g., not "humanized") and not from (either in whole or in part) a non-human species. A human antibody or functional antibody fragment can be derived from a human or can be a synthetic human antibody. A "synthetic human antibody" is defined herein as an antibody having a sequence derived, in whole or in part, *in silico* from synthetic sequences that are based on the analysis of known human antibody sequences. *In silico* design of a human antibody sequence or fragment thereof can be achieved, for example, by analyzing a database of human antibody or antibody fragment sequences and devising a polypeptide sequence utilizing the data obtained therefrom. Another example of a human antibody or functional antibody fragment is one that is encoded by a nucleic acid isolated from a library of antibody sequences of human origin (*i.e.*, such library being based on antibodies taken from a human natural source).

[0020] A "humanized antibody" or functional humanized antibody fragment is defined herein as one that is (i) derived from a non-human source (e.g., a transgenic mouse which bears a heterologous immune system), which antibody is based on a human germline sequence; or (ii) chimeric, wherein the variable domain is derived from a non-human origin and the constant domain is derived from a human origin or (iii) CDR-grafted, wherein the CDRs of the variable domain are from a non-human origin, while one or more frameworks of the variable domain are of human origin and the constant domain (if any) is of human origin.

[0021] The term "chimeric antibody" or functional chimeric antibody fragment is defined herein as an antibody molecule which has constant antibody regions derived from, or corresponding to, sequences found in one species and variable antibody regions derived from another species. Preferably, the constant antibody regions are derived from, or corresponding to, sequences found in humans, e.g. in the human germ line or somatic cells, and the variable antibody regions (e.g. VH, VL, CDR or FR regions) are derived from sequences found in a non-human animal, e.g. a mouse, rat, rabbit or hamster.

[0022] In one aspect of the present invention, the antibody specific for GM-CSF is a chimeric, humanized or human antibody.

[0023] In one aspect of the present invention, the antibody specific for GM-CSF is a humanized antibody.

[0024] As used herein, an antibody "binds specifically to", "specifically binds to", is "specific to/for" or "specifically recognizes" an antigen (here, GM-CSF) if such antibody is able to discriminate between such antigen and one or more reference antigen(s), since binding specificity is not an absolute, but a relative property. The reference antigen(s) may be one or more closely related antigen(s), which are used as reference points, e.g. IL3, IL5, IL-4, IL13 or M-CSF. In its most general form (and when no defined reference is mentioned), "specific binding" is referring to the ability of the antibody to discriminate between the antigen of interest and an unrelated antigen, as determined, for example, in accordance with one of the following methods. Such methods comprise, but are not limited to Western blots, ELISA-, RIA-, ECL-, IRMA-tests and peptide scans. For example, a standard ELISA assay can be carried out. The scoring may be carried out by standard color development (e.g. secondary antibody with horseradish peroxidase and tetramethyl benzidine with hydrogenperoxide). The reaction in certain wells is scored by the optical density, for example, at 450 nm. Typical background (=negative reaction) may be 0.1 OD; typical positive reaction may be 1 OD. This means the difference positive/negative can be more than 10-fold. Typically, determination of binding specificity is performed by using not a single reference antigen, but a set of about three to five unrelated antigens, such as milk powder, BSA, transferrin or the like. Additionally, "specific binding" may relate to the ability of an antibody to discriminate between different parts of its target antigen, e.g. different domains or regions of GM-CSF, or between one or more key amino acid residues or stretches of amino acid residues of GM-CSF.

[0025] Also, as used herein, an "immunoglobulin" (Ig) hereby is defined as a protein belonging to the class IgG, IgM, IgE, IgA, or IgD (or any subclass thereof), and includes all conventionally known antibodies and functional fragments thereof. A "functional fragment" of an antibody/immunoglobulin hereby is defined as a fragment of an antibody/immunoglobulin (e.g., a variable region of an IgG) that retains the antigen-binding region. An "antigen-binding region" of an antibody typically is found in one or more hypervariable region(s) of an antibody, *i.e.*, the CDR-1, -2, and/or -3 regions; however, the variable "framework" regions can also play an important role in antigen binding, such as by providing a scaffold for the CDRs. Preferably, the "antigen-binding region" comprises at least amino acid residues 4 to 103 of the

variable light (VL) chain and 5 to 109 of the variable heavy (VH) chain, more preferably amino acid residues 3 to 107 of VL and 4 to 111 of VH, and particularly preferred are the complete VL and VH chains (amino acid positions 1 to 109 of VL and 1 to 113 of VH; numbering according to WO 97/08320). A preferred class of immunoglobulins for use in the present invention is IgG. "Functional fragments" of the invention include the domain of a F(ab')₂ fragment, a Fab fragment, scFv or constructs comprising single immunoglobulin variable domains or single domain antibody polypeptides, e.g. single heavy chain variable domains or single light chain variable domains. The F(ab')₂ or Fab may be engineered to minimize or completely remove the intermolecular disulphide interactions that occur between the C_{H1} and C_L domains.

[0026] An antibody of the invention may be derived from a recombinant antibody library that is based on amino acid sequences that have been designed *in silico* and encoded by nucleic acids that are synthetically created. *In silico* design of an antibody sequence is achieved, for example, by analyzing a database of human sequences and devising a polypeptide sequence utilizing the data obtained therefrom. Methods for designing and obtaining *in silico*-created sequences are described, for example, in Knappik et al, J. Mol. Biol. 296:57, 2000; Krebs et al, J. Immunol. Methods. 254:67, 2001; Rothe et al, J. Mol. Biol. 376:1182, 2008 and U.S. Patent No. 6,300,064 issued to Knappik et al 2000 supra.

[0027] Any antibody specific for GM-CSF may be used with the present invention. Exemplary antibodies are disclosed in US 11/914,599.

[0028] Other exemplary antibodies include antibodies comprising an amino acid sequence of a heavy chain variable region as depicted in SEQ ID NO:1 or an amino acid sequence of a light chain variable region as depicted in SEQ ID NO:2. Yet other exemplary antibodies include antibodies which are derived from antibodies comprising a heavy chain variable region as depicted in SEQ ID NO:1 or an amino acid sequence of a light chain variable region as depicted in SEQ ID NO:2. Yet other exemplary antibodies include antibodies which have the same specificity and/or bind to the same epitope as antibodies comprising a heavy chain variable region as depicted in SEQ ID NO:1 or an amino acid sequence of a light chain variable region as depicted in SEQ ID NO:2. Yet other exemplary antibodies include antibodies which comprise a heavy chain variable region which is at least 70 %, at least 80 %, at least 90 % or at least 95 % homologous to the sequence depicted in SEQ ID NO:1. Yet other exemplary antibodies include antibodies which comprise a light chain variable region which is at least 70 %, at least 80 %, at least 90 % or at least 95 % homologous to the sequence depicted in SEQ ID NO:2.

SEQ ID NO:1:

Met Glu Leu Ile Met Leu Phe Leu Leu Ser Gly Thr Ala Gly Val His
Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly
Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp
Tyr Asn Ile His Trp Val Lys Gln Ser His Gly Lys Ser Leu Asp Trp
Ile Gly Tyr Ile Ala Pro Tyr Ser Gly Gly Thr Gly Tyr Asn Gln Glu
Phe Lys Asn Arg Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala
Tyr Met Glu Leu Arg Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr
Cys Ala Arg Arg Asp Arg Phe Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
Thr Thr Leu Arg Val Ser Ser Val Ser Gly Ser

SEQ ID NO:2:

Met Gly Phe Lys Met Glu Ser Gln Ile Gln Val Phe Val Tyr Met Leu
 Leu Trp Leu Ser Gly Val Asp Gly Asp Ile Val Met Ile Gln Ser Gln
 5 Lys Phe Val Ser Thr Ser Val Gly Asp Arg Val Asn Ile Thr Cys Lys
 Ala Ser Gln Asn Val Gly Ser Asn Val Ala Trp Leu Gln Gln Lys Pro
 10 Gly Gln Ser Pro Lys Thr Leu Ile Tyr Ser Ala Ser Tyr Arg Ser Gly
 Arg Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Ile
 15 Leu Thr Ile Thr Thr Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys
 Gln Gln Phe Asn Arg Ser Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu
 20 Glu Leu Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro
 Ser Ser Lys Gly Glu Phe

[0029] Alternative exemplary antibodies that can be used in the present invention are antibodies comprising an amino acid sequence of a heavy chain variable region as depicted in SEQ ID NO:3 or an amino acid sequence of a light chain variable region as depicted in SEQ ID NO:4. Other exemplary antibodies include antibodies which are derived from antibodies comprising a heavy chain variable region as depicted in SEQ ID NO:3 or an amino acid sequence of a light chain variable region as depicted in SEQ ID NO:4. Yet other exemplary antibodies include antibodies which have the same specificity and/or bind to the same epitope as antibodies comprising a heavy chain variable region as depicted in SEQ ID NO:3 or an amino acid sequence of a light chain variable region as depicted in SEQ ID NO:4. Yet other exemplary antibodies include antibodies which comprise a heavy chain variable region which is at least 70 %, at least 80 %, at least 90 % or at least 95 % homologous to the sequence depicted in SEQ ID NO:3. Yet other exemplary antibodies include antibodies which comprise a light chain variable region which is at least 70 %, at least 80 %, at least 90 % or at least 95 % homologous to the sequence depicted in SEQ ID NO:4.

SEQ ID NO. 3: heavy MOR

**QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSGIENKYAGGA
 40 TYAAASVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCARGFGTDFWGQGTLVTVSS**

SEQ ID NO:4: light MOR

**DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKRPSGIPERFSGSNS
 45 GNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKLTVLGQ**

[0030] In one aspect, the present invention provides an antibody specific for GM-CSF wherein the antibody comprises a heavy chain variable region which is at least 90% homologous to the amino acid sequence of SEQ ID NO:3, and a light chain variable region which is at least 90% homologous to the amino acid sequence of SEQ ID NO:4.

[0031] In one aspect, the present invention provides an antibody specific for GM-CSF wherein the antibody comprises a heavy chain variable region which is at least 95% homologous to the amino acid sequence of SEQ ID NO:3, and a light chain variable region which is at least 95% homologous to the amino acid sequence of SEQ ID NO:4.

[0032] In one aspect, the present invention provides an antibody specific for GM-CSF wherein the antibody comprises the heavy chain variable region amino acid sequence of SEQ ID NO:3, and the light chain variable region amino acid sequence of SEQ ID NO:4.

[0033] Alternative exemplary antibodies that can be used in the present invention are antibodies comprising a H-CDR3

7

Ser Gly Leu Ile Ile Asp Asn Leu Asn Pro
 1 5 10

(SEQ ID NO:15),

and

Ser Gly Leu Ile Ala Val Tyr Phe Asp Tyr
 1 5 10

(SEQ ID NO:16).

[0034] Preferably, the antibodies comprising a H-CDR3 sequence selected from any one of SEQ ID NOs. 5-16, additionally comprise the following H-CDR1 sequence:

Asp Tyr Leu Leu His
 1 5

(SEQ ID NO:17),

and/or the following H-CDR2 sequence:

Trp Leu Asn Pro Tyr Ser Gly Asp Thr Asn Tyr Ala Gln Lys Phe Gln
 1 5 10 15
 Gly

(SEQ ID NO:18),

and/or the following L-CDR1 sequence:

Arg Ala Ser Gln Asn Ile Arg Asn Ile Leu Asn
 1 5 10

(SEQ ID NO:19),

and/or the following L-CDR2 sequence:

Ala Ala Ser Asn Leu Gln Ser
 1 5

(SEQ ID NO:20),

and/or the following L-CDR3 sequence:

Gln Gln Ser Tyr Ser Met Pro Arg Thr
 1 5

(SEQ ID NO:21).

[0035] Alternative exemplary antibodies that can be used in the present invention are antibodies comprising the following L-CDR1 sequence:

5 Arg Ala Ser His Arg Val Ser Ser Asn Tyr Leu Ala
1 5 10
(SEQ ID NO:22),

10 and/or the following L-CDR2 sequence:

Gly Ala Ser Asn Arg Ala Thr
1 5 (SEQ ID NO:23),

and/or the following L-CDR3 sequence:

20 Gln Gln Tyr Ala Ser Ser Pro Val Thr
1 5 (SEQ ID NO:24),

and/or the following H-CDR1 sequence:

(SEQ ID NO:25),

Gly Tyr Ile Phe Pro Thr Phe Ala Leu His
1 5 10

and/or the following H-CDR2 sequence:

35 Ser Ile Asn Thr Ala Ser Gly Lys Thr Lys Phe Ser Thr Lys Phe Gln
1 5 10 15
(SEQ ID NO:26),

and/or the following H-CDR3 sequence:

Asp Arg Phe Gln Asn Ile Met Ala Thr Ile Leu Asp Val
1 5 10

(SEQ ID NO:27).

[0036] Preferably said antibody comprise all the CRDs of SEQ ID NOs. 22-27.

50 **[0037]** Also disclosed are methods for the treatment of osteoarthritis in a subject, said method comprising the step of administering a GM-CSF antagonist to said subject, wherein the antagonist is an antibody specific for GM-CSF. "Subject", as used in this context refers to any mammal, including rodents, such as mouse or rat, and primates, such as cynomolgus monkey (*Macaca fascicularis*), rhesus monkey (*Macaca mulatta*) or humans (*Homo sapiens*). Preferably the subject is a primate, most preferably a human.

55 **[0038]** Also disclosed is a composition comprising such a GM-CSF antagonist capable of antagonizing the ability of GM-CSF from activating, proliferating, inducing growth and/or survival of cells in a subject suffering from osteoarthritis, or being suspected of suffering from osteoarthritis, said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents. Anti-GM-CSF antibodies of the present invention may antagonize any of the roles of GM-CSF in osteoarthritis.

[0039] Also disclosed is a method for the prophylaxis of osteoarthritis in a subject, said method comprising administering a GM-CSF antagonist to said subject, wherein the antagonist is an antibody specific for GM-CSF. "Prophylaxis" as used in this context refers to methods which aim to prevent the onset of a disease or which delay the onset of a disease.

[0040] In one aspect, the present invention provides a composition comprising a GM-CSF antagonist for use in the treatment of osteoarthritis, wherein said GM-CSF antagonist is an antibody specific for GM-CSF and further wherein said composition further comprises one or more pharmaceutically acceptable carriers and/or diluents.

[0041] Also disclosed is the use of such a GM-CSF antagonist in the preparation of a medicament in the treatment of osteoarthritis.

[0042] The compositions of the present invention are preferably pharmaceutical compositions comprising a GM-CSF antagonist, wherein the GM-CSF antagonist is an antibody specific for GM-CSF, and a pharmaceutically acceptable carrier, diluent or excipient, for use in the treatment of osteoarthritis. Such carriers, diluents and excipients are well known in the art, and the skilled artisan will find a formulation and a route of administration best suited to treat a subject with an antibody specific for GM-CSF.

[0043] Also disclosed are genetically engineered mice having a GM-CSF $-/-$ genotype. The terms "knock-out" mouse, a mouse "disrupted in" a certain gene, and a mouse with a " $-/-$ genotype" are used interchangeably in the present invention and are art recognized. Respective animals are deficient in a respective gene, here GM-CSF, on both alleles of the chromosome.

Example 1:

Generation of a GM-CSF $-/-$ mouse

[0044] The generation of GM-CSF $-/-$ mice is described in Stanley et al (1994). Proc. Natl. Acad. Sci. USA 91:5592. Briefly, chimeric mice were generated by microinjection of 129/OLA-derived ES cells (H-2b) with a disrupted GM-CSF gene into C57BL/6 (H-2b) host blastocysts. Germline transmitters of the mutated GM-CSF allele were crossed with C57BL/6 mice for 11 generations, giving GM-CSF $+/-$ mice that were interbred to yield the GM-CSF $-/-$, GM-CSF $+/-$, and GM-CSF $+/+$ mice used for the experiments. GM-CSF genotype status was determined by PCR analysis of tail DNA. Animals were fed standard rodent chow and water ad libitum and were housed with same sex littermates in sawdust-lined cages. Mice of both sexes were consigned to experiments at 8 to 15 wk of age

Example 2:

Validation of GM-CSF as a target for osteoarthritis

[0045] GM-CSF $-/-$ mice were compared to C57/BL6 mice (see e.g. Mills et al, J Immunol 164:6166-6173, 2000) in an experimental model of osteoarthritis.

[0046] Method: Mice (n=10 per group) received an intra-articular injection of collagenase in the leftknee on day -2 and day 0 (Blom et al, Arthritis Rheum 56:147-157, 2007). At day 42 the mice were killed, the knee joints collected, fixed, de-calcified, embedded in paraffin and cut at 7 μ m with a microtome. Slides were then stained with Safranin-O/Fast Green and Haematoxylin and Eosin to demonstrate joint pathology. Pathology investigated includes: cartilage damage, synovitis, osteophyte formation and joint deformation.

[0047] The scoring system used for cartilage pathology was as follows:

Grade

- | | |
|-----|---|
| 0 | Normal |
| 1 | Irregular but intact |
| 1.5 | Irregular with rough surface |
| 2 | Superficial fibrillation |
| 2.5 | Superficial fibrillation with reduced cells in cartilage layer |
| 3 | Vertical fissures |
| 3.5 | Branching and/or horizontal fissures, tidemark ruptures |
| 4 | Cartilage loss not extending to the tide mark |
| 4.5 | Cartilage loss extending to the tide mark |
| 5 | Cartilage loss beyond the tide mark but not extending to the bone |
| 5.5 | Cartilage loss extending to the bone |
| 6 | Bone loss/remodeling/deformation |

Stage

- 1 <10% area damaged
- 2 10-25% area damaged
- 3 25-50% area damaged
- 4 50-75% area damaged

[0048] The grade was multiplied by the stage to give the score.

[0049] This scoring system is based on a recognized method to assess OA histopathology in clinical and experimental OA. See Pritzker et al, Osteoarthritis Cartilage 14:13-29, 2006. Grade is defined as OA depth progression into cartilage. Stage is defined as the horizontal extent of cartilage involvement, i.e. how much of the cartilage is affected. Grade is multiplied by the stage to give the score to give an overall score, so as to represent a combined assessment of OA severity and extent. Up to six sections are scored per mouse.

[0050] Results: Inspection of these joints showed that the GM-CSF^{-/-} mice show less knee joint pathology than the control mice, indicating the role of GM-CSF in normal osteoarthritis pathology and progression. Pathology observed in the C57/BL6 mice includes severe damage to the cartilage layer, osteophyte formation, joint deformation and synovitis. The GM-CSF^{-/-} mice showed no osteophyte formation or joint deformation and much less cartilage damage and synovitis.

[0051] Quantitative data on joint damage in different regions are shown in Figure 1. Representative histology is shown in Figures 2 (healthy control knees), 3 (C57/BL6 left knees) and 4 (GM-CSF^{-/-} left knees). GM-CSF gene -deficient mice developed less collagenase-induced OA pathology, compared to C57BL/6 mice.

[0052] In summary, GM-CSF^{-/-} mice showed strongly decreased knee joint pathology compared to C57/BL6 mice in an experimental model of osteoarthritis and validated GM-CSF as a drug target for therapeutic intervention for osteoarthritis.

Example 3:

Therapeutic effectiveness of GM-CSF antagonists in the treatment of OA

[0053] In this experiment we used a monoclonal antibody specific for GM-CSF to demonstrate that a GM-CSF antagonist can be effective to treat osteoarthritis.

Collagen-induced OA mouse model:

[0054] C57BL/6 mice were given 1 unit of collagenase type VII intra-articularly into the right knee on days 0 and 2 to induce joint instability (see Blom et al. (2004) Osteoarthritis Cartilage. 12; 627-35).

Anti-GM-CSF antibody treatment:

[0055] 20 mice were randomly divided into 2 groups (10 mice/group).

- Group 1 (n = 10): anti-GM-CSF antibody (22E9)
- Group 2 (n = 10): IgG2a isotype control antibody.

[0056] Mice were treated intraperitoneally, three times per week for 6 weeks with 250 µg/mouse/treatment anti-GM-CSF antibody (22E9) or IgG2a isotype control antibody. Treatment started 4 days before the induction of OA (prophylactic), i.e. mice were treated on day -4, day -2, day 0 (the day of the first collagenase injection), then 3 times per week until the end of the experiment at 6 weeks. At weeks 2, 4 and 6, mice were bled. Serum will be checked for antibody content and immunogenicity against 22E9. Both, the control antibody and the anti-GM-CSF antibody were purified to contain less than 10 Endotoxin Units/ml.

[0057] The antibody 22E9 was used as an exemplary anti-GM-CSF antibody. 22E9, which is of IgG2a isotype, is a rat anti-mouse GM-CSF-specific antibody. 22E9 was purchased from AbD Serotec (Martinsried, Germany; Cat.No. 1023501). Alternative suppliers exist, e.g. eBioscience (San Diego, CA, USA, Cat. No. 14-7331).

Histology:

[0058] 6- weeks post final injections, histology was performed on the mice knee joints. The knee joints were collected, fixed, de-calcified, embedded in paraffin and cut at 7 µm with a microtome. Slides were stained with Safranin-O/Fast Green and Haematoxylin and Eosin to demonstrate joint pathology. Pathology investigated included: cartilage damage,

synovitis, osteophyte formation and joint deformation.

[0059] The same scoring system as in Example 2 was used for cartilage pathology. Grade was multiplied by the stage to give the score.

[0060] The following scoring system was used for synovitis (Synovial layer scoring system):

- 0 No changes compared to normal joints
- 1 Thickening of the synovial lining and some influx of inflammatory cells
- 2 Thickening of the synovial lining and intermediate influx of inflammatory cells
- 3 Profound thickening of the synovial lining and maximal observed influx of inflammatory cells

Pain measurements:

[0061] An indicator of pain used for OA models is differential distribution of weight measured using an Incapacitance Meter. This instrument measures changes in weight distribution between the operated and contralateral, unoperated hind limb. Mice were allowed to acclimatize to the equipment on three occasions prior to the experiment. Weight placed on each hind limb was measured over a 5 second period. Three separate measurements taken per mouse for each time point then averaged. Measurements were performed 2 times per week throughout the experiment. Results are expressed as collagenase injected limb/control limb x 100.

Results:

[0062] For all areas analyzed in histology (except the Medial Femur), i.e. the Lateral Femur, the Lateral Tibia, and the Medial Tibia, there was a clear trend towards less disease in mice treated with anti-GM-CSF antibody. Results are depicted in Figure 5.

[0063] Assessment of the weight distribution, as a measure of pain associated with the arthritis, showed a significant shift in weight away from the arthritic knee from day 27 onwards in the anti-GM-CSF mAb-treated group compared to the control mAb-treated group. Results are depicted in Figure 6.

[0064] Mice treated with a GM-CSF antagonist showed less disease as compared to mice treated with the control antibody. Mice treated with the GM-CSF antagonist also showed significantly less pain in the latter stages of disease compared to mice treated with the control antibody. Mice treated with the isotype control antibody showed significant increased signs of osteoarthritis as compared to the mice which received the GM-CSF-specific antibody. This demonstrates that GM-CSF antagonists are effective in the treatment of OA.

Example 4:

Therapeutic effectiveness of a GM-CSF specific antibody comprising SEQ ID NOs. 1 or 2

[0065] Example 3 is repeated, whereby as GM-CSF antagonist, a GM-CSF specific antibody comprising an amino acid sequence of a heavy chain variable region as depicted in SEQ ID NO:1 or comprising an amino acid sequence of a light chain variable region as depicted in SEQ ID NO:2 is used. Another species than mouse may be used, in particular a species to which the antibody used in this experiment is cross reactive. Preferably the animal species used in this experiment is rat.

[0066] The animals treated with the isotype control antibody shows significant increased signs of osteoarthritis as compared to the animals which received a GM-CSF specific antibody comprising an amino acid sequence of a heavy chain variable region as depicted in SEQ ID NO:1 or comprising an amino acid sequence of a light chain variable region as depicted in SEQ ID NO:2. This demonstrates the effectiveness of the antibodies in the treatment of OA.

Example 5:

Therapeutic effectiveness of a GM-CSF specific antibody comprising SEQ ID NOs. 3 or 4

[0067] Example 3 is repeated. As GM-CSF antagonist, a GM-CSF specific antibody comprising an amino acid sequence of a heavy chain variable region as depicted in SEQ ID NO:3 or comprising an amino acid sequence of a light chain variable region as depicted in SEQ ID NO:4 is used. Another species than mouse may be used, in particular a species to which the antibody used in this experiment is cross reactive. Preferably the animal species used in this experiment is rat.

[0068] The animals, e.g. rat, treated with the isotype control antibody show significant increased signs of osteoarthritis as compared to the animals which received a GM-CSF specific antibody comprising an amino acid sequence of a heavy chain variable region as depicted in SEQ ID NO:3 or comprising an amino acid sequence of a light chain variable region

as depicted in SEQ ID NO:4. This demonstrates the effectiveness of the antibodies in the treatment of OA.

Example 6:

Therapeutic effectiveness of a GM-CSF specific antibodies comprising SEQ ID NOs. 5-20

[0069] Example 3 is repeated. As GM-CSF antagonist, a GM-CSF specific antibody comprising a H-CDR3 sequence selected from any one of SEQ ID NOs. 5-16 is used. Preferably, said antibodies additionally comprise the H-CDR1 sequence of SEQ ID NO:16, and/or the H-CDR2 sequence of SEQ ID NO:17, and/or the L-CDR1 sequence of SEQ ID NO:18, and/or the L-CDR2 sequence of SEQ ID NO:19, and/or the L-CDR3 sequence of SEQ ID NO:20. Another species than mouse may be used, in particular a species to which the antibody used in this experiment is cross reactive. Preferably the animal species used in this experiment is rat.

[0070] The animals, e.g. rat, treated with the isotype control antibody show significant increased signs of osteoarthritis as compared to the animals which received a GM-CSF specific antibody according to the present example. This demonstrates the effectiveness of the antibodies in the treatment of OA.

Example 7:

Therapeutic effectiveness of a GM-CSF specific antibodies comprising SEQ ID NOs. 21-26

[0071] Example 3 is repeated. As GM-CSF antagonist, a GM-CSF specific antibody comprising the L-CDR1 sequence of SEQ ID NO:22, and/or the L-CDR2 sequence of SEQ ID NO:23, and/or the L-CDR3 sequence of SEQ ID NO:24, and/or the H-CDR1 sequence of SEQ ID NO:25, and/or the H-CDR2 sequence of SEQ ID NO:26, and/or the H-CDR3 sequence of SEQ ID NO:27 is used. Preferably said antibody comprise all the CRDs of SEQ ID NOs. 22-27. Another species than mouse may be used, in particular a species to which the antibody used in this experiment is cross reactive. Preferably the animal species used in this experiment is rat.

[0072] The animals, e.g. rat, treated with the isotype control antibody show significant increased signs of osteoarthritis as compared to the animals which received a GM-CSF specific antibody according to the present example. This demonstrates the effectiveness of the antibodies in the treatment of OA.

Example 8:

Therapeutic effectiveness of antibodies specific for the GM-CSF receptor

[0073] Example 3 is repeated with the difference that a monoclonal antibody specific for the GM-CSF receptor is used instead of a monoclonal antibody specific for the GM-CSF.

[0074] As GM-CSF antagonist, a GM-CSF receptor specific antibody comprising an amino acid sequence of a H-CDR3 sequence depicted in any one of SEQ ID No's.:27-45 is used. Another species than mouse may be used, in particular a species to which the antibody used in this experiment is cross reactive. Preferably the animal species used in this experiment is rat.

[0075] The animals, e.g. rat, treated with the isotype control antibody show significant increased signs of osteoarthritis as compared to the animals which received a GM-CSF receptor specific antibody according to the present example. This demonstrates the effectiveness of the antibodies in the treatment of OA.

Example 9:

Clinical trial

[0076] A clinical trial is performed in adult patients suffering from osteoarthritis of the knee. The objective of the randomized, double-blind, placebo-controlled clinical trial is to determine the comparative differences between the GM-CSF antagonists of the present invention and placebo in overall pain relief and quality of life in a total sample of 30 patients with diagnosed osteoarthritis (OA) of the knee. Another objective is to determine the safety and tolerability of the GM-CSF antagonists of the present invention as determined by the adverse events, physical examination and vital signs.

Methods:

[0077] Thirty patients (about 15 adult males and 15 adult females), aged 40 and over, with a clinical diagnosis of osteoarthritis of the knee(s) and verified knee pain for at least 15 days in the month prior to testing are enrolled in the

study. Patients receive a therapeutically effective amount of GM-CSF antagonists or a placebo (e.g. once every two weeks for about six months).

[0078] The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC; Bellamy et al, J Rheumatol 15(12):1833-40, 1988) and the SF-36v2 Quality of Life instrument scales (Quality Metric Health Outcomes Solutions, Lincoln, RI) are used in the study. The WOMAC is a disease-specific, self-administered, health status measure. It probes clinically-important symptoms in the areas of pain, stiffness and physical function in patients with osteoarthritis of the hip and/or knee. The index consists of 24 questions (5-pain, 2-stiffness and 17-physical function) and can be completed in less than 5 minutes. The WOMAC is a valid, reliable and sensitive instrument for the detection of clinically important changes in health status following a variety of interventions (pharmacologic, nutritional, surgical, physiotherapy, etc.). The WOMAC questionnaire is valid for assessing the effects of intervention on hip or knee osteoarthritis. The SF-36v2 Quality of Life instrument is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures and a preference-based health utility index. It is a generic measure, as opposed to one that targets a specific age, disease, or treatment group. Accordingly, the SF-36v2 has proven useful in surveys of general and specific populations, comparing the relative burden of diseases, and in differentiating the health benefits produced by a wide range of different treatments. The SF-36v2 yields information on the following aspects and subsets of health; Physical Health (comprised of physical functioning, role-physical, bodily pain and general health) and Mental Health (comprised of vitality, social functioning, role- emotional and mental health).

Results:

[0079] Change in bodily pain: The improvement in SF-36v2 bodily pain is statistically significant in patients treated with the GM-CSF antagonists of the present invention as compared with placebo. A higher score is better because it means the patient feels less pain after taking the product. There is a statistical significant improvement in the bodily-pain score in the group that received the GM-CSF antagonists of the present invention versus the placebo group.

[0080] Change in role-physical score: The superior effect of the GM-CSF antagonists of the present invention compared with the placebo is statistically significant in week 8, week 12, and week 20 in terms of role limitations due to physical health (role physical). A higher score is better because it means that the patient noticed a physical improvement and a reduction in the limitations suffered in activities of daily living. There is a statistical significant improvement in the role-physical score in the group that received the GM-CSF antagonists of the present invention versus the placebo group.

[0081] Change in the total WOMAC score: The total WOMAC score of the group treated with the GM-CSF antagonists of the present invention is statistical significantly better than the total WOMAC score of the placebo group (a lower score is better).

[0082] Change in WOMAC ADL: The improvement in activities of daily living (measured as a WOMAC ADL sub-score) is greater in the group treated with the GM-CSF antagonists of the present invention than in the placebo group. There is an statistically significant improvement in the WOMAC ADL score in the group treated with the GM-CSF antagonists of the present invention compared to the placebo group (a lower score is better).

Conclusions:

[0083] The clinical trial shows the efficacy of the GM-CSF antagonists of the present invention in improving the quality of life of patients with osteoarthritis of the knee. The results of the clinical trial also show the product's safety and tolerance, given that no serious adverse effects were found.

[0084] The efficacy of the GM-CSF antagonists of the present invention can also be established through studies in other species to which the GM-CSF antagonists of the present invention are cross-reactive (e.g. on horses in order to evaluate joint movement); and by using in vitro studies to determine the ability of GM-CSF antagonists of the present invention to inhibit IL-1 -induced aggrecan degradation, conducting the assay on chondrocyte cultures.

BIBLIOGRAPHY

[0085]

- Bellamy et al, J Rheumatol 15(12):1833-40, 1988
- Blom et al, Arthritis Rheum 56:147-157, 2007
- Ghose et al, J Combin Chem: 1:55-68, 1999
- Knappik et al, J. Mol. Biol. 296:57, 2000
- Krebs et al, J. Immunol. Methods. 254:67, 2001
- Lipinski et al, Adv Drug Del Rev 23:3-25, 1997

EP 2 376 121 B1

Mills et al, J Immunol 164:6166-6173, 2000
Pritzker et al, Osteoarthritis Cartilage 14:13-29, 2006
Rothe et al, J. Mol. Biol. 376:1182, 2008

5 SEQUENCE LISTING

[0086]

10 <110> THE UNIVERSITY OF MELBOURNE
HAMILTON, John (US Only)
COOK, Andrew (US Only)

<120> OSTEOARTHRITIS TREATMENT

15 <130> 30898448/EJH

<150> US 61/139,679

<151> 2008-12-22

20 <150> US 61/164,486

<151> 2009-03-30

<160> 46

25 <170> Patent In version 3.5

<210> 1

<211> 140

<212> PRT

30 <213> artificial

<220>

<223> amino acid sequence of heavy chain variable region

35 <400> 1

Met Glu Leu Ile Met Leu Phe Leu Leu Ser Gly Thr Ala Gly Val His

40 1 5 10 15

45

50

55

EP 2 376 121 B1

Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly
20 25 30

5

Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp
10 35 40 45

15

Tyr Asn Ile His Trp Val Lys Gln Ser His Gly Lys Ser Leu Asp Trp
50 55 60

20

Ile Gly Tyr Ile Ala Pro Tyr Ser Gly Gly Thr Gly Tyr Asn Gln Glu
25 65 70 75 80

30

Phe Lys Asn Arg Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala
85 90 95

35

Tyr Met Glu Leu Arg Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr
40 100 105 110

45

Cys Ala Arg Arg Asp Arg Phe Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln
115 120 125

50

Gly Thr Thr Leu Arg Val Ser Ser Val Ser Gly Ser
130 135 140

55

<210> 2
<211> 150
<212> PRT
<213> artificial

EP 2 376 121 B1

<220>

<223> amino acid sequence of light chain variable region

<400> 2

5

Met Gly Phe Lys Met Glu Ser Gln Ile Gln Val Phe Val Tyr Met Leu

1 5 10 15

10

Leu Trp Leu Ser Gly Val Asp Gly Asp Ile Val Met Ile Gln Ser Gln

15

20 25 30

20

Lys Phe Val Ser Thr Ser Val Gly Asp Arg Val Asn Ile Thr Cys Lys

35 40 45

25

Ala Ser Gln Asn Val Gly Ser Asn Val Ala Trp Leu Gln Gln Lys Pro

30

50 55 60

35

Gly Gln Ser Pro Lys Thr Leu Ile Tyr Ser Ala Ser Tyr Arg Ser Gly

65 70 75 80

40

45

50

55

EP 2 376 121 B1

Arg Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Ile
85 90 95

5

Leu Thr Ile Thr Thr Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys
10 100 105 110

15

Gln Gln Phe Asn Arg Ser Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu
115 120 125

20

Glu Leu Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro
25 130 135 140

30

Ser Ser Lys Gly Glu Phe
145 150

35

<210> 3
<211> 117
<212> PRT
<213> artificial

40

<220>
<223> amino acid sequence of heavy chain variable region
<400> 3

45

50

55

EP 2 376 121 B1

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

5

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 10 20 25 30

15

Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

20

Ser Gly Ile Glu Asn Lys Tyr Ala Gly Gly Ala Thr Tyr Tyr Ala Ala
 25 50 55 60

30

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
 65 70 75 80

35

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
 85 90 95

40

Tyr Cys Ala Arg Gly Phe Gly Thr Asp Phe Trp Gly Gln Gly Thr Leu
 100 105 110

45

50

Val Thr Val Ser Ser
 115

55

<210> 4
 <211> 105
 <212> PRT

EP 2 376 121 B1

<213> artificial

<220>

<223> amino acid sequence of light chain variable region

5

<400> 4

Asp Ile Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln

10

1 5 10 15

15

Thr Ala Arg Ile Ser Cys Ser Gly Asp Ser Ile Gly Lys Lys Tyr Ala

20 25 30

20

Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr

25

35 40 45

30

Lys Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser

50 55 60

35

Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Glu Asp Glu

65 70 75 80

40

Ala Asp Tyr Tyr Cys Ser Ala Trp Gly Lys Gly Met Val Phe Gly Gly

85 90 95

45

Gly Thr Lys Leu Thr Val Leu Gly Gln

50

100 105

<210> 5

<211> 10

<212> PRT

55

<213> artificial

<220>

<223> amino acid sequence of Homo sapiens CDR3 (H-CDR3)

EP 2 376 121 B1

<400> 5

Ser Gly Leu Ile Phe Asp Tyr Trp Leu Asp

5 1 5 10

<210> 6

<211> 10

<212> PRT

10 <213> artificial

<220>

<223> amino acid sequence of Homo sapiens CDR3 (H-CDR3)

15 <400> 6

Ser Gly Leu Ile Ile Asp Ala Leu Ser Pro

20 1 5 10

<210> 7

<211> 10

<212> PRT

25 <213> artificial

<220>

<223> amino acid sequence of Homo sapiens CDR3 (H-CDR3)

30 <400> 7

Thr Ser Leu Met Ser Ile Tyr Phe Asp Tyr

35 1 5 10

<210> 8

<211> 10

<212> PRT

<213> artificial

<220>

<223> amino acid sequence of Homo sapiens CDR3 (H-CDR3)

<400> 8

45 Ser Gly Leu Leu Phe Leu Tyr Phe Asp Tyr

1 5 10

<210> 9

50 <211> 10

<212> PRT

<213> artificial

<220>

55 <223> amino acid sequence of Homo sapiens CDR3 (H-CDR3)

<400> 9

EP 2 376 121 B1

Ser Gly Leu Ile Asn Leu Gly Met His Pro

1 5 10

5 <210> 10
<211> 10
<212> PRT
<213> artificial

10 <220>
<223> amino acid sequence of Homo sapiens CDR3 (H-CDR3)

<400> 10

Ser Gly Leu Ile Phe Asp Ala Leu Arg Asp

1 5 10

20 <210> 11
<211> 10
<212> PRT
<213> artificial

25 <220>
<223> amino acid sequence of Homo sapiens CDR3 (H-CDR3)

<400> 11

Ser Gly Leu Ile Phe Asp Lys Leu Thr Ser

1 5 10

35 <210> 12
<211> 10
<212> PRT
<213> artificial

40 <220>
<223> amino acid sequence of Homo sapiens CDR3 (H-CDR3)

<400> 12

Ser Gly Leu Ile Asn Leu His Phe Asp Thr

1 5 10

50 <210> 13
<211> 10
<212> PRT
<213> artificial

55 <220>
<223> amino acid sequence of Homo sapiens CDR3 (H-CDR3)

<400> 13

EP 2 376 121 B1

Ser Thr His Phe Ser Ala Tyr Phe Asp Tyr
1 5 10

5 <210> 14
<211> 10
<212> PRT
<213> artificial

10 <220>
<223> amino acid sequence of Homo sapiens CDR3 (H-CDR3)

<400> 14

15 Ser Gly Leu Ile Met Asp Lys Leu Asp Asn
1 5 10

20 <210> 15
<211> 10
<212> PRT
<213> artificial

25 <220>
<223> amino acid sequence of Homo sapiens CDR3 (H-CDR3)

<400> 15

30 Ser Gly Leu Ile Ile Asp Asn Leu Asn Pro
1 5 10

35 <210> 16
<211> 10
<212> PRT
<213> artificial

40 <220>
<223> amino acid sequence of Homo sapiens CDR3 (H-CDR3)

<400> 16

45 Ser Gly Leu Ile Ala Val Tyr Phe Asp Tyr
1 5 10

50 <210> 17
<211> 5
<212> PRT
<213> artificial

<220>
<223> amino acid sequence of heavy CDR1 (H-CDR1)

55 <400> 17

EP 2 376 121 B1

Asp Tyr Leu Leu His

1 5

5 <210> 18
<211> 17
<212> PRT
<213> artificial

10 <220>
<223> amino acid sequence of heavy CDR2 (H-CDR2)

<400> 18

15 Trp Leu Asn Pro Tyr Ser Gly Asp Thr Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15

20

Gly

25 <210> 19
<211> 11
<212> PRT
<213> artificial

30 <220>
<223> amino acid sequence of light CDR1 (L-CDR1)

<400> 19

35 Arg Ala Ser Gln Asn Ile Arg Asn Ile Leu Asn
1 5 10

40 <210> 20
<211> 7
<212> PRT
<213> artificial

45 <220>
<223> amino acid sequence of light CDR2 (L-CDR2)

<400> 20

50 Ala Ala Ser Asn Leu Gln Ser
1 5

55 <210> 21
<211> 9
<212> PRT
<213> artificial

<220>

EP 2 376 121 B1

<223> amino acid sequence of light CDR3 (L-CDR3)

<400> 21

5 Gln Gln Ser Tyr Ser Met Pro Arg Thr
 1 5

<210> 22

10 <211> 12

<212> PRT

<213> artificial

<220>

15 <223> amino acid sequence of light CDR1 (L-CDR1)

<400> 22

20 Arg Ala Ser His Arg Val Ser Ser Asn Tyr Leu Ala
 1 5 10

<210> 23

<211> 7

25 <212> PRT

<213> artificial

<220>

30 <223> amino acid sequence of light CDR2 (L-CDR2)

<400> 23

 Gly Ala Ser Asn Arg Ala Thr
35 1 5

<210> 24

<211> 9

<212> PRT

40 <213> artificial

<220>

<223> amino acid sequence of light CDR3 (L-CDR3)

<400> 24

 Gln Gln Tyr Ala Ser Ser Pro Val Thr
50 1 5

<210> 25

<211> 10

<212> PRT

<213> artificial

55 <220>

<223> amino acid sequence of heavy CDR3 (H-CDR3)

EP 2 376 121 B1

<400> 25

Gly Tyr Ile Phe Pro Thr Phe Ala Leu His

5 1 5 10

<210> 26

<211> 16

<212> PRT

10 <213> artificial

<220>

<223> amino acid sequence of heavy CDR2 (H-CDR2)

15 <400> 26

Ser Ile Asn Thr Ala Ser Gly Lys Thr Lys Phe Ser Thr Lys Phe Gln

20 1 5 10 15

<210> 27

<211> 13

<212> PRT

25 <213> artificial

<220>

<223> amino acid sequence of heavy CDR3 (H-CDR3)

30 <400> 27

Asp Arg Phe Gln Asn Ile Met Ala Thr Ile Leu Asp Val

35 1 5 10

<210> 28

<211> 11

<212> PRT

40 <213> artificial

<220>

<223> amino acid sequence of heavy CDR3 (H-CDR3)

<400> 28

45 Val Gly Ser Phe Ser Gly Ile Ala Tyr Arg Pro

1 5 10

<210> 29

50 <211> 11

<212> PRT

<213> artificial

<220>

55 <223> amino acid sequence of heavy CDR3 (H-CDR3)

<400> 29

EP 2 376 121 B1

Val Gly Ser Phe Ser Gly Pro Ala Leu Arg Pro

1 5 10

5 <210> 30
<211> 11
<212> PRT
<213> artificial

10 <220>
<223> amino acid sequence of heavy CDR3 (H-CDR3)

<400> 30

Val Gly Ser Phe Ser Pro Pro Thr Tyr Gly Tyr

1 5 10

20 <210> 31
<211> 11
<212> PRT
<213> artificial

25 <220>
<223> amino acid sequence of heavy CDR3 (H-CDR3)

<400> 31

Val Gly Ser Phe Ser Gly Tyr Pro Tyr Arg Pro

1 5 10

35 <210> 32
<211> 11
<212> PRT
<213> artificial

40 <220>
<223> amino acid sequence of heavy CDR3 (H-CDR3)

<400> 32

Val Gly Ser Phe Ser Pro Leu Thr Leu Gly Leu

1 5 10

50 <210> 33
<211> 11
<212> PRT
<213> artificial

55 <220>
<223> amino acid sequence of heavy CDR3 (H-CDR3)

<400> 33

EP 2 376 121 B1

Val Gly Ser Phe Ser Gly Pro Val Tyr Gly Leu

1 5 10

5 <210> 34
<211> 11
<212> PRT
<213> artificial

10 <220>
<223> amino acid sequence of heavy CDR3 (H-CDR3)

<400> 34

Val Gly Ser Phe Ser Pro Pro Ala Tyr Arg Pro

1 5 10

20 <210> 35
<211> 11
<212> PRT
<213> artificial

25 <220>
<223> amino acid sequence of heavy CDR3 (H-CDR3)

<400> 35

Val Gly Ser Phe Ser Pro Val Thr Tyr Gly Leu

1 5 10

35 <210> 36
<211> 11
<212> PRT
<213> artificial

40 <220>
<223> amino acid sequence of heavy CDR3 (H-CDR3)

<400> 36

Val Gly Ser Phe Ser Gly Leu Ala Tyr Arg Pro

1 5 10

50 <210> 37
<211> 11
<212> PRT
<213> artificial

55 <220>
<223> amino acid sequence of heavy CDR3 (H-CDR3)

<400> 37

EP 2 376 121 B1

Val Gly Ser Phe Ser Pro Ile Thr Tyr Gly Leu
1 5 10

5 <210> 38
<211> 11
<212> PRT
<213> artificial

10 <220>
<223> amino acid sequence of heavy CDR3 (H-CDR3)

<400> 38

15 Val Gly Ser Phe Ser Gly Trp Ala Phe Asp Tyr
1 5 10

20 <210> 39
<211> 11
<212> PRT
<213> artificial

25 <220>
<223> amino acid sequence of heavy CDR3 (H-CDR3)

<400> 39

30 Val Gly Ser Phe Ser Gly Trp Ala Phe Asp Tyr
1 5 10

35 <210> 40
<211> 11
<212> PRT
<213> artificial

40 <220>
<223> amino acid sequence of heavy CDR3 (H-CDR3)

<400> 40

45 Leu Gly Ser Val Thr Ala Trp Ala Phe Asp Tyr
1 5 10

50 <210> 41
<211> 11
<212> PRT
<213> artificial

55 <220>
<223> amino acid sequence of heavy CDR3 (H-CDR3)

<400> 41

EP 2 376 121 B1

Ala Gly Ser Ile Pro Gly Trp Ala Phe Asp Tyr

1 5 10

5 <210> 42
<211> 11
<212> PRT
<213> artificial

10 <220>
<223> amino acid sequence of heavy CDR3 (H-CDR3)

<400> 42

Val Gly Ser Phe Ser Pro Leu Thr Met Gly Leu

1 5 10

20 <210> 43
<211> 11
<212> PRT
<213> artificial

25 <220>
<223> amino acid sequence of heavy CDR3 (H-CDR3)

<400> 43

Val Gly Ser Phe Ser Pro Leu Thr Met Gly Leu

1 5 10

35 <210> 44
<211> 11
<212> PRT
<213> artificial

40 <220>
<223> amino acid sequence of heavy CDR3 (H-CDR3)

<400> 44

Val Gly Ser Phe Ser Gly Pro Ala Leu His Leu

1 5 10

50 <210> 45
<211> 11
<212> PRT
<213> artificial

55 <220>
<223> amino acid sequence of heavy CDR3 (H-CDR3)

<400> 45

EP 2 376 121 B1

Val Gly Ser Val Ser Arg Ile Thr Tyr Gly Phe

1 5 10

5 <210> 46
<211> 11
<212> PRT
<213> artificial

10 <220>
<223> amino acid sequence of heavy CDR3 (H-CDR3)

<400> 46

15 Val Gly Ser Phe Ser Pro Leu Thr Leu Gly Leu
1 5 10

20 Claims

1. An antagonist of GM-CSF for use in the treatment of osteoarthritis, wherein the antagonist is an antibody specific for GM-CSF.
- 25 2. A composition comprising a GM-CSF antagonist for use in the treatment of osteoarthritis, wherein the antagonist is an antibody specific for GM-CSF and further wherein said composition further comprises one or more pharmaceutically acceptable carriers and/or diluents.
3. An antibody for use according to claim 1 or claim 2, wherein the antibody is a chimeric, humanised or human antibody.
- 30 4. An antibody for use according to claim 3, wherein the antibody is a humanised antibody.
5. An antibody for use according to any of claims 1- 4, wherein the antibody comprises a heavy chain variable region which is at least 90% homologous to the amino acid sequence of SEQ ID NO: 3, and a light chain variable region which is at least 90% homologous to the amino acid sequence of SEQ ID NO: 4.
- 35 6. An antibody for use according to claim 5, wherein the antibody comprises a heavy chain variable region which is at least 95% homologous to the amino acid sequence of SEQ ID NO: 3, and a light chain variable region which is at least 95% homologous to the amino acid sequence of SEQ ID NO: 4.
- 40 7. An antibody for use according to claim 5, wherein the antibody comprises the heavy chain variable region amino acid sequence of SEQ ID NO: 3, and the light chain variable region amino acid sequence of SEQ ID NO: 4.

45 Patentansprüche

1. Antagonist von GM-CSF zur Verwendung bei der Behandlung von Osteoarthritis, wobei der Antagonist ein für GM-CSF spezifischer Antikörper ist.
- 50 2. Zusammensetzung, umfassend einen GM-CSF-Antagonisten zur Verwendung bei der Behandlung von Osteoarthritis, wobei der Antagonist ein für GM-CSF spezifischer Antikörper ist und wobei die Zusammensetzung ferner ein(en) oder mehrere pharmazeutisch annehmbare(n/s) Träger und/oder Verdünnungsmittel umfasst.
3. Antikörper zur Verwendung gemäss Anspruch 1 oder Anspruch 2, wobei der Antikörper ein chimärer, humanisierter oder menschlicher Antikörper ist.
- 55 4. Antikörper zur Verwendung gemäss Anspruch 3, wobei der Antikörper ein humanisierter Antikörper ist.

5. Antikörper zur Verwendung gemäss einem der Ansprüche 1 bis 4, wobei der Antikörper eine variable schwere Ketten-Region, die zu mindestens 90 % zur Aminosäuresequenz von SEQ ID NO: 3 homolog ist, und eine variable leichte Ketten-Region, die zu mindestens 90 % zur Aminosäuresequenz von SEQ ID NO: 4 homolog ist, umfasst.

- 5 6. Antikörper zur Verwendung gemäss Anspruch 5, wobei der Antikörper eine variable schwere Ketten-Region, die zu mindestens 95 % zur Aminosäuresequenz von SEQ ID NO: 3 homolog ist, und eine variable leichte Ketten-Region, die zu mindestens 95 % zur Aminosäuresequenz von SEQ ID NO: 4 homolog ist, umfasst.

- 10 7. Antikörper zur Verwendung gemäss Anspruch 5, wobei der Antikörper die variable schwere Ketten-Region-Aminosäuresequenz von SEQ ID NO: 3 und die variable leichte Ketten-Region-Aminosäuresequenz von SEQ ID NO: 4 umfasst.

Revendications

- 15 1. Antagoniste de GM-CSF pour une utilisation dans le traitement de l'arthrose, dans lequel l'antagoniste est un anticorps spécifique pour le GM-CSF.

- 20 2. Composition comprenant un antagoniste de GM-CSF pour une utilisation dans le traitement de l'arthrose, dans laquelle l'antagoniste est un anticorps spécifique pour le GM-CSF et en outre dans laquelle ladite composition comprend en outre un ou plusieurs supports et/ou diluants pharmaceutiquement acceptables.

- 25 3. Anticorps pour une utilisation selon la revendication 1 ou la revendication 2, dans lequel l'anticorps est un anticorps chimérique, humanisé ou humain.

4. Anticorps pour une utilisation selon la revendication 3, dans lequel l'anticorps est un anticorps humanisé.

- 30 5. Anticorps pour une utilisation selon l'une quelconque des revendications 1 à 4, dans lequel l'anticorps comprend une zone variable à chaîne lourde qui est au moins à 90 % homologue à la séquence d'acide aminé de SEQ. ID N°3 et une zone variable à chaîne légère qui est au moins à 90 % homologue à la séquence d'acide aminé de SEQ. ID N°4.

- 35 6. Anticorps pour une utilisation selon la revendication 5, dans lequel l'anticorps comprend une zone variable à chaîne lourde qui est au moins à 95 % homologue à la séquence d'acide aminé de SEQ. ID N°3 et une zone variable à chaîne légère qui est au moins à 95 % homologue à la séquence d'acide aminé de SEQ. ID N°4.

- 40 7. Anticorps pour une utilisation selon la revendication 5, dans lequel l'anticorps comprend la séquence d'acide aminé de zone variable à chaîne lourde SEQ. ID N°3 et la séquence d'acide aminé de zone variable à chaîne légère de SEQ. ID N°4.

40

45

50

55




Figure 1




Figure 2




Figure 3




Figure 4





Figure 5



Results are expressed as the mean \pm SEM.

* $p=0.04$, ** $p=0.04$, *** $p=0.02$, **** $p=0.005$, Unpaired t-test.

Figure 6

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 060234412 A [0007]
- US 20020141994 A1 [0007]
- WO 9708320 A [0025]
- US 6300064 B, Knappik [0026]
- US 11914599 B [0027]
- US 61139679 B [0086]
- US 61164486 B [0086]

Non-patent literature cited in the description

- BLOM et al. *Current Drug Targets*, 2008, vol. 8, 283 [0005]
- AMOS et al. *Rheumatology*, 2004, vol. 10, 1201-1209 [0008]
- VAN HOLTEN et al. *Arthritis Res Ther*, 2004, vol. 6, R239-R249 [0008]
- COOK et al. *Arthritis Res*, 2001, vol. 3, 293-298 [0008]
- GHOSE et al. *J Combin Chem*, 1999, vol. 1, 55-68 [0018] [0085]
- LIPINSKI et al. *Adv Drug Del Rev*, 1997, vol. 23, 3-25 [0018] [0085]
- KNAPPIK et al. *J. Mol. Biol.*, 2000, vol. 296, 57 [0026] [0085]
- KREBS et al. *J. Immunol. Methods*, 2001, vol. 254, 67 [0026] [0085]
- ROTHE et al. *J. Mol. Biol.*, 2008, vol. 376, 1182 [0026] [0085]
- STANLEY et al. *Proc. Natl. Acad. Sci. USA*, 1994, vol. 91, 5592 [0044]
- MILLS et al. *J Immunol*, 2000, vol. 164, 6166-6173 [0045] [0085]
- BLOM et al. *Arthritis Rheum*, 2007, vol. 56, 147-157 [0046] [0085]
- PRITZKER et al. *Osteoarthritis Cartilage*, 2006, vol. 14, 13-29 [0049] [0085]
- BLOM et al. *Osteoarthritis Cartilage*, 2004, vol. 12, 627-35 [0054]
- BELLAMY et al. *J Rheumatol*, 1988, vol. 15 ((12)), 1833-40 [0078] [0085]

Szabadalmi igénypontok

1. GM-CSF antagonistája oszteoarthritis kezelésében történő alkalmazásra, ahol az antagonista egy GM-CSF-re specifikus antitest.

2. Készítmény, amely tartalmazza az oszteoarthritis kezelésében történő alkalmazásra szolgáló GM-CSF antagonistát, ahol az antagonista egy GM-CSF-re specifikus antitest, és ahol a készítmény tartalmaz továbbá egy vagy több gyógyszerészetileg elfogadható hordozót és/vagy hígítószer.

3. Antitest alkalmazásra az 1. vagy 2. igénypont szerint, ahol az antitest kimerá antitest, humanizált antitest vagy humán antitest.

4. Antitest alkalmazásra a 3. igénypont szerint, ahol az antitest humanizált antitest.

5. Antitest alkalmazásra az 1-4. igénypontok bármelyike szerint, ahol az antitest tartalmaz nehézlánc variábilis régiót, amely legalább 90%-ban homológ a SEQ ID NO:3 aminosav-szekvenciájával, és könnyűlánc variábilis régiót, amely legalább 90%-ban homológ a SEQ ID NO:4 aminosav-szekvenciájával.

6. Antitest alkalmazásra az 5. igénypont szerint, ahol az antitest tartalmaz nehézlánc variábilis régiót, amely legalább 95%-ban homológ a SEQ ID NO:3 aminosav-szekvenciájával, és könnyűlánc variábilis régiót, amely legalább 95%-ban homológ a SEQ ID NO:4 aminosav-szekvenciájával.

7. Antitest alkalmazásra az 5. igénypont szerint, ahol az antitest tartalmazza a SEQ ID NO:3 aminosav-szekvenciájú nehézlánc variábilis régiót és a SEQ ID NO:4 aminosav-szekvenciájú könnyűlánc variábilis régiót.